Molecular diagnosis of parathyroid carcinoma: a reality in the near future

Bibliography

• Westin G, Bjorklund P, Akerstrom G. Molecular genetics of parathyroid disease. World J Surg 2009;6(11):2224-33
   Web of Science ®Google Scholar
• Akerstrom G, Hellman P, Bjorklund P. Parathyroid carcinoma. Chapter 22 In: Hay I, Wass JAH, editors. Clinical endocrinology. 2nd edition. Blackwell; Chichester, UK: 2008. p. 180-4
   Google Scholar
• Miki H, Sumitomo M, Inoue H, Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery 1996;120:897-901
   PubMed Web of Science ®Google Scholar
• Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol 1999;8:155-65
   PubMed Web of Science ®Google Scholar
• Rao SR, Shaha AR, Singh B, Management of cancer of the parathyroid. Acta Otolaryngol 2002;122:448-52
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86:538-44
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Daskalakis M, Melissas J, Tsiftsis DD. Parathyroid carcinoma: clinical presentation and management. Am J Otolaryngol Head Neck Med Surg 2009;30:277-80
   Web of Science ®Google Scholar
• Lee PK, Jarosek SL, Virnig BA, Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007;109:1736-41
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, McHenry CR. Parathyroid carcinoma. J Surg Oncol 2005;89:136-42
   PubMed Web of Science ®Google Scholar
• Altenahr E, Saeger W. Light and electron microscopy of parathyroid carcinoma: report of three cases. Virchows Arch A Pathol Pathol Anat 1973;360:107-22
   PubMedGoogle Scholar
• Ebner S, Emerson CH. Documentation of parathyroid carcinoma fifteen years after resection of a parathyroid “adenoma”. Clin Endocrinol 1993;38:659-61
   PubMed Web of Science ®Google Scholar
• Bichel P, Thomsen OF, Askjaer AA, Nielsen HE. Light and electron microscopic investigation of parathyroid carcinoma during dedifferentiation. Survey and study of a case. Virchows Arch A Pathol Anat Histol 1980;386:363-70
   PubMed Web of Science ®Google Scholar
• Hakaim AG, Esselstyn CB. Parathyroid carcinoma: 50-year experience at the Cleveland Clinic Foundation. Cleve Clin J Med 1993;60:331-5
   PubMed Web of Science ®Google Scholar
• Dionisio P, Stramignoni E, Passaroni G, Recurrent secondary hyperparathyroidism due to parathyroid carcinoma: usefulness of Ki-67 immunostaining in the diagnosis of a malignant parathyroid tumor. Nephron 1996;74(4):720-3
   PubMedGoogle Scholar
• Okamoto T, Iihara M, Obara T, Tsukada T. Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg 2009;33(11):2343-54
   PubMed Web of Science ®Google Scholar
• Arnold A, Marx SJ. Familial hyperparathyroidism (Including MEN, FHH, and HPT-JT). Chapter 76 In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th edition. Clifford J Rosen (Editor-in-Chief), Julient E. Compston, M.D., FRCP (Senior Associate Editor), Jane B. Lian, Ph.D. (Senior Associate Editor)A publication of the American Society for Bone and Mineral Research, New Jersey; Wiley, 2008. p. 361-6 Clifford J. Rosen (Editor-in-Chief), Juliet E. Compston, M.D., FRCP (Senior Associate Editor), Jane B. Lian, Ph.D. (Senior Associate Editor), Wiley publisher, United States Corporate Headquarters 111 River Street Hoboken, NJ 07030-5774
   Google Scholar
• O'Neal P, Mowschenson P, Connolly J, Hasselgren PO. Large parathyroid tumors have an increased risk of atypia and carcinoma. Ann J Surg 2011; [Epub ahead of print]
   PubMedGoogle Scholar
• Schantz A, Castleman B. Parathyroid carcinoma: a study of 70 cases. Cancer 1973;31:600-5
   PubMed Web of Science ®Google Scholar
• DeLellis RA. Parathyroid carcinoma: an overview. Adv Anat Pathol 2005;12:53-61
   PubMed Web of Science ®Google Scholar
• Erickson LA, Jin L, Wollan P, Parathyroid hyperplasia, adenomas, and carcinomas: Differential expression of p27Kip1 protein. Am J Surg Pathol 1999;23:288-95
   PubMed Web of Science ®Google Scholar
• Bergero N, De Pompa R, Sacerdote C, Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908-14
   PubMed Web of Science ®Google Scholar
• DeLellis RA. Tumors of the parathyroid glands. Atlas of Tumor Pathology. 3rd series, fascicle 6. Armed Forces Institute of Pathology, Washington, DC; 1993
   Google Scholar
• Falchetti A, Becherini L, Martineti V, Telomerase Repeat Amplification Protocol (TRAP): a new molecular marker for parathyroid carcinoma. Biochem Biophys Res Commun 1999;265:252-5
   PubMed Web of Science ®Google Scholar
• Falchetti A, Franchi A, Bordi C, Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 2005;20:410-18
   PubMed Web of Science ®Google Scholar
• Haven CJ, van Puijenbrock M, Karperien M, Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 2004;202:86-94
   PubMed Web of Science ®Google Scholar
• Fernandez-Ranvier GG, Khanafshar E, Tacha D, Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 2009;115:334-444
   PubMed Web of Science ®Google Scholar
• Hunt JL, Carty SE, Yim JH, Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol 2005;29:1049-55
   PubMed Web of Science ®Google Scholar
• Rogers SE, Perrier ND. Parathyroid carcinoma. Curr Opin Oncol 2006;18:16-22
   PubMed Web of Science ®Google Scholar
• Rawat N, Khetan N, Williams DW, Baxter JN. Parathyroid carcinoma. Br J Surg 2005;92:1345-53
   PubMed Web of Science ®Google Scholar
• Valimaki S, Forsberg L, Farnebo LO, Larsson C. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 2002;21:727-35
   PubMed Web of Science ®Google Scholar
• Falchetti A, Marini F, Giusti F, DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. J Intern Med 2009;266:69-83
   PubMed Web of Science ®Google Scholar
• Carpten JD, Robbins CM, Villablanca A, HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumors syndrome. Nat Genet 2002;32:676-80
   PubMed Web of Science ®Google Scholar
• Marcocci C, Cetani F, Rubin MR, Parathyroid Carcinoma. J Bone Miner Res 2008;23(12):1869-80
   PubMed Web of Science ®Google Scholar
• Dotzenrath C, The T, Farnebo F, Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996;8:3194-6
   Google Scholar
• Pearce SH, Trump D, Wooding W, Loss of heterozygosity study at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol (Oxf) 1996;45:195-200
   PubMed Web of Science ®Google Scholar
• Cetani F, Pardi E, Viacava P, A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004;60:99-106
   PubMed Web of Science ®Google Scholar
• Shattuck TM, Kim TS, Costa J, Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 2003;59:180-9
   PubMed Web of Science ®Google Scholar
• Farnebo F, Enberg U, Grimelius L, Tumour-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 1997;82:3481-6
   PubMed Web of Science ®Google Scholar
• Hosokawa Y, Pollak MR, Brown EM, Arnold A. Mutational analysis of the extracellular Ca(2?)-sensing receptor gene in human parathyroid tumours. J Clin Endocrinol Metab 1995;80:3107-10
   PubMed Web of Science ®Google Scholar
• Degenhardt S, Toell A, Weidemann W, Point mutations of the human parathyroid calcium receptor gene are not responsible for non-suppressible renal hyperparathyroidism. Kidney Int 1998;53:556-61
   PubMed Web of Science ®Google Scholar
• Cetani F, Pinchera A, Pardi E, No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res 1999;14:878-82
   PubMed Web of Science ®Google Scholar
• Witteveen JE, Harndy NA, Dekkers OM, Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis of parathyroid carcinoma. Mod Pathol 2011;24(5):688-97
   PubMed Web of Science ®Google Scholar
• Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996;81(5):1736-9
   PubMed Web of Science ®Google Scholar
• Vasef MA, Brynes RK, Sturm M, Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999;12(4):412-16
   PubMed Web of Science ®Google Scholar
• Vargas MP, Vargas HI, Kleiner DE, Merino MJ. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 1997;10:12-17
   PubMed Web of Science ®Google Scholar
• Juhlin CC, Haglund F, Villablanca A, Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-b in parathyroid carcinomas. Int J Oncol 2009;34:481-92
   PubMed Web of Science ®Google Scholar
• Juhlin CC, Nilsson IL, Johansson K, Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 2010;21(3):166-77
   PubMed Web of Science ®Google Scholar
• DeLellis RA. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classifications of Tumors. IARC Press; Lyon, France: 2004. p. 124-7
   Google Scholar
• Howell VM, Gill A, Clarkson A, Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009;94:434-41
   PubMed Web of Science ®Google Scholar
• Gagel RF, Marx SJ. Multiple endocrine neoplasia. Chapter 40 In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams Textbook of Endocrinology. 11th edition. Saunders Ed(s); Philadelphia: 2008. p. 1705-46
   Google Scholar
• Falchetti A, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2005. Available from: http://www.genetests.org
   Google Scholar
• Marx SJ. Multiple endocrine neoplasia type 1. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th edition. McGraw-Hill; New York, USA: 2001. p. 943-66
   Google Scholar
• Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21
   PubMed Web of Science ®Google Scholar
• Chandrasekharappa SC, Guru SC, Manickam P, Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276(5311):404-7
   PubMed Web of Science ®Google Scholar
• Sato M, Miyauchi A, Namihira H, A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. Endocrine 2000;12(3):223-6
   PubMed Web of Science ®Google Scholar
• Dionisi S, Minisola S, Pepe J, Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002;77(8):866-9
   PubMed Web of Science ®Google Scholar
• Agha A, Carpenter R, Bhattacharya S, Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 2007;30(2):145-9
   PubMed Web of Science ®Google Scholar
• Gracanin A, Dreijerink KM, van der Luijt RB, Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. Cancer Res 2009;69(16):6371-4
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Satta MA, Simmgen M, Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol (Oxf) 1997;47(6):747-51
   PubMed Web of Science ®Google Scholar
• Mallette LE, Malini S, Rappaport MP, Kirkland JL. Familial cystic parathyroid adenomatosis. Ann Intern Med 1987;107:54-60
   PubMed Web of Science ®Google Scholar
• Shattuck TM, Valimaki S, Obara T, Somatic and germ-line mutations of the HRTP2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349:1722-9
   PubMed Web of Science ®Google Scholar
• Hewitt KM, Sharma PK, Samowitz W, Hobbs M. Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 2007;116:928-33
   Google Scholar
• Howell VM, Haven CJ, Kahnoski K, HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet 2003;40:657-63
   PubMed Web of Science ®Google Scholar
• Gill AJ, Clarkson A, Gimm O, Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006;30:1140-9
   PubMed Web of Science ®Google Scholar
• Cetani F, Ambrogini E, Viacava P, Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histological diagnosis of parathyroid carcinoma? Eur J Endocrinol 2007;156:547-54
   PubMed Web of Science ®Google Scholar
• Haven CJ, van Puijenbroek M, Tan MH, Identification of MEN1 and HRPT2 somatic mutations in paraffin embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 2007;67:370-6
   PubMed Web of Science ®Google Scholar
• Tan MH, Morrison C, Wang P, Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004;10:6629-37
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, McHenry CR. Parathyroid carcinoma. J Surg Oncol 2005;89:136-42
   PubMed Web of Science ®Google Scholar
• Rozenblatt-Rosen O, Hughes CM, Nannnepaga SJ, The parafibromin tumour suppressor protein is part of a human Paf1 complex. Mol Cell Biol 2005;25:612-20
   PubMed Web of Science ®Google Scholar
• Juhlin CC, Hoog A. Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse? Int J Endocrinol 2010;2010:324964
   PubMed Web of Science ®Google Scholar
• Woodard GE, Lin L, Zhang Parafibromin, product of the hyperparathyroidism-jaw tumour syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 2005;24:1272-6
   PubMed Web of Science ®Google Scholar
• Juhlin CC, Villablanca A, Sandelin K, Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 2007;14:501-12
   PubMed Web of Science ®Google Scholar
• Bifsha P, Landry K, Ashmarina L, Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway. Cell Death Differ 2007;14:511-23
   Google Scholar
• Caballero OL, Resto V, Patturajan M, Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene 2002;21:3003-10
   PubMed Web of Science ®Google Scholar
• Ovaa H, Kessler BM, Rolen U, Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 2004;101:2253-8
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Nakayama S, Torikoshi Y, High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci 2006;97:523-9
   PubMed Web of Science ®Google Scholar
• Selvarajan S, Sii LH, Lee A, Parafibromin expression in breast cancer: a novel marker for prognostication? J Clin Pathol 2008;61:64-7
   PubMed Web of Science ®Google Scholar
• Wang P, Bowl MR, Bender S, Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol 2008;28:2930-40
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszck MA, Prowse KR, Specific association of human telomerase activity with immortal cells and cancer. Science 1994;226:2011-15
   Web of Science ®Google Scholar
• Shay JW. Molecular pathogenesis of aging and cancer: are telomeres and telomerase the connection? J Cell Physiol 1997;173(2):266-70
   PubMed Web of Science ®Google Scholar
• Orlando C, Gelmini S. Telomerase in endocrine and endocrine-dependent tumors. J Steroid Biochem Mol Biol 2001;78:201-14
   PubMed Web of Science ®Google Scholar
• Vezzosi D, Bouisson M, Escourrou G, Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours. Clin Endocrinol 2006;64:63-7
   PubMed Web of Science ®Google Scholar
• Kammori M, Nakamura K-I, Kanauchi H, Consistent decrease in telomere length in parathyroid tumors but alteration in telomerase activity limited to malignancies: preliminary report. World J Surg 2002;26:1083-7
   PubMed Web of Science ®Google Scholar
• Kammori M, Nakamura K-I, Ogawa T, Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by in situ hybridization with a new oligonucleotide probe. Clin Endocrinol (Oxf) 2003;58:43-8
   PubMed Web of Science ®Google Scholar
• Onoda N, Ogisawa K, Ishikawa T, Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid. Surg Today 2004;34:389-93
   PubMed Web of Science ®Google Scholar
• Velin AK, Herder A, Johansson KJM, Telomerase is not activated in human hyperplastic and adenomatous parathyroid tissue. Eur J Endocrinol 2001;145:161-4
   PubMed Web of Science ®Google Scholar